Poly Medicure Ltd (POLYMED) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Poly Medicure reported strong Q3 FY25 results with consolidated revenue growth of 24.9%, reaching Rs. 424 crores compared to Rs. 339 crores in Q3 FY24.
- Consolidated EBITDA increased from Rs. 91 crores to Rs. 116 crores, with a margin improvement of 65 bps.
- PAT grew from Rs. 65 crores to Rs. 85 crores.
- The company maintains a strong net cash position of Rs. 1,074 crores, including Rs. 900 crores from the QIP.
- Poly Medicure added 23 new sales team members during the quarter.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.